Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fimasartan - Boryung Pharmaceutical

Drug Profile

Fimasartan - Boryung Pharmaceutical

Alternative Names: Arakhor; BR 1007; BR-1017A; BR-A-657; BR-A-657-K; BR1015-1; BR1015-2; BR1017-1; Kanarb

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boryung
  • Developer Boryung; Labcorp Drug Development; R-Pharm
  • Class Antihyperlipidaemics; Antihypertensives; Pyrimidinones; Small molecules; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Essential hypertension; Hypertension
  • Phase III Kidney disorders
  • No development reported Diabetic nephropathies; Dyslipidaemias; Myocardial infarction

Most Recent Events

  • 18 Feb 2024 Boryung Pharmaceutical completes a phase I trial (In volunteers) in South Korea (PO) (NCT06184269)
  • 23 Dec 2023 Boryung Pharmaceutical initiates enrolment in a phase I trial (In volunteers) in South Korea (PO) (NCT06184269)
  • 06 Oct 2023 Boryung Pharmaceutical completes a phase I trial for Hypertension (In Volunteers) in South Korea (PO, Tablet) (NCT06008028)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top